1099 Stock Overview
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
No risks detected for 1099 from our risk checks.
My Notes
NewNotes are coming soon
Sinopharm Group Co. Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$19.68 |
| 52 Week High | HK$21.35 |
| 52 Week Low | HK$14.60 |
| Beta | 0.76 |
| 1 Month Change | -4.00% |
| 3 Month Change | 28.13% |
| 1 Year Change | 8.97% |
| 3 Year Change | -25.45% |
| 5 Year Change | -38.60% |
| Change since IPO | 6.26% |
Recent News & Updates
Sinopharm Group (HKG:1099) Has Some Way To Go To Become A Multi-Bagger
Jan 19
Is Sinopharm Group (HKG:1099) A Risky Investment?
Nov 18Returns At Sinopharm Group (HKG:1099) Appear To Be Weighed Down
Oct 03Recent updates
Sinopharm Group (HKG:1099) Has Some Way To Go To Become A Multi-Bagger
Jan 19Is Sinopharm Group (HKG:1099) A Risky Investment?
Nov 18Returns At Sinopharm Group (HKG:1099) Appear To Be Weighed Down
Oct 03Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Jul 31Estimating The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)
Jul 10Slowing Rates Of Return At Sinopharm Group (HKG:1099) Leave Little Room For Excitement
Jun 05We Think Sinopharm Group (HKG:1099) Can Stay On Top Of Its Debt
Apr 11A Look At The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)
Mar 21Sinopharm Group (HKG:1099) Hasn't Managed To Accelerate Its Returns
Mar 03Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Jan 09Sinopharm Group Co., Ltd.'s (HKG:1099) Intrinsic Value Is Potentially 28% Above Its Share Price
Dec 19Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled
Dec 01These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well
Sep 23A Look At The Fair Value Of Sinopharm Group Co., Ltd. (HKG:1099)
Sep 10Return Trends At Sinopharm Group (HKG:1099) Aren't Appealing
Aug 28Sinopharm Group (HKG:1099) Is Increasing Its Dividend To HK$0.84
Jun 13Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly
Jun 06Is Sinopharm Group Co., Ltd. (HKG:1099) Expensive For A Reason? A Look At Its Intrinsic Value
May 24Sinopharm Group's (HKG:1099) Returns Have Hit A Wall
May 11Have Insiders Been Selling Sinopharm Group Co., Ltd. (HKG:1099) Shares?
Mar 20We Think Sinopharm Group (HKG:1099) Is Taking Some Risk With Its Debt
Mar 05You Have To Love Sinopharm Group Co., Ltd.'s (HKG:1099) Dividend
Feb 18
Should You Be Impressed By Sinopharm Group's (HKG:1099) Returns on Capital?
Feb 03Should You Use Sinopharm Group's (HKG:1099) Statutory Earnings To Analyse It?
Jan 19At HK$19.00, Is It Time To Put Sinopharm Group Co., Ltd. (HKG:1099) On Your Watch List?
Jan 06What Type Of Shareholders Make Up Sinopharm Group Co., Ltd.'s (HKG:1099) Share Registry?
Dec 25Read This Before Buying Sinopharm Group Co., Ltd. (HKG:1099) Shares
Dec 15We Think Sinopharm Group (HKG:1099) Can Stay On Top Of Its Debt
Dec 04Sinopharm Group's (HKG:1099) Stock Price Has Reduced 43% In The Past Five Years
Nov 25Reflecting on Sinopharm Group's (HKG:1099) Share Price Returns Over The Last Three Years
Aug 22Is Weakness In Sinopharm Group Co., Ltd. (HKG:1099) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
Aug 10Will Weakness in Sinopharm Group Co., Ltd.'s (HKG:1099) Stock Prove Temporary Given Strong Fundamentals?
Aug 10What To Know Before Buying Sinopharm Group Co., Ltd. (HKG:1099) For Its Dividend
Jul 26Sinopharm Group Co., Ltd.'s (HKG:1099) Business Is Trailing The Market But Its Shares Aren't
Jul 13How Much Is Sinopharm Group's (HKG:1099) CEO Getting Paid?
Jun 28Shareholder Returns
| 1099 | HK Healthcare | HK Market | |
|---|---|---|---|
| 7D | -0.2% | 0.4% | -3.4% |
| 1Y | 9.0% | -44.4% | -12.3% |
Return vs Industry: 1099 exceeded the Hong Kong Healthcare industry which returned -44.3% over the past year.
Return vs Market: 1099 exceeded the Hong Kong Market which returned -12.3% over the past year.
Price Volatility
| 1099 volatility | |
|---|---|
| 1099 Average Weekly Movement | 4.6% |
| Healthcare Industry Average Movement | 8.8% |
| Market Average Movement | 7.8% |
| 10% most volatile stocks in HK Market | 15.5% |
| 10% least volatile stocks in HK Market | 3.8% |
Stable Share Price: 1099 is less volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 1099's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 112,859 | Yong Liu | https://www.sinopharmgroup.com.cn |
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People’s Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail drug stores, and clinics.
Sinopharm Group Co. Ltd. Fundamentals Summary
| 1099 fundamental statistics | |
|---|---|
| Market Cap | HK$61.41b |
| Earnings (TTM) | HK$9.17b |
| Revenue (TTM) | HK$632.67b |
6.7x
P/E Ratio0.1x
P/S RatioIs 1099 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1099 income statement (TTM) | |
|---|---|
| Revenue | CN¥546.15b |
| Cost of Revenue | CN¥500.52b |
| Gross Profit | CN¥45.63b |
| Other Expenses | CN¥37.71b |
| Earnings | CN¥7.91b |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.54 |
| Gross Margin | 8.35% |
| Net Profit Margin | 1.45% |
| Debt/Equity Ratio | 68.4% |
How did 1099 perform over the long term?
See historical performance and comparison